Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity.

Experts suggest that testing for this protein, called neuropeptide Y (NPY), could help predict how heart failure is likely to progress. Researchers hope a blood test could be used to help guide ...

By receiving ghrelin, the hypothalamus in the brain senses hunger and produces 'hunger signaling' through the action of neuropeptide Y (NPY). The hunger signaling activates neurons in the ...